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Summary Background. Data regarding response to treatment in lymphomatoid papulosis
(LyP) are scarce.
Aim. To assess the daily clinical practice approach to LyP and the response to first-
line treatments.
Methods. This was a retrospective study enrolling 252 patients with LyP.
Results. Topical steroids, methotrexate and phototherapy were the most common
first-line treatments, prescribed for 35%, 20% and 14% of the patients, respectively.
Complete response (CR) was achieved in 48% of treated patients. Eczematous lesions
significantly increased relative risk (RR) of not achieving CR (RR = 1.76; 95% CI
1.16–2.11). Overall median time to CR was 10 months (95% CI 6–13 months), and
78% of complete responders showed cutaneous relapse; both results were similar for
all treatment groups (P > 0.05). Overall estimated median disease-free survival
(DFS) was 11 months (95% CI 9–13 months) but DFS for patients treated with
phototherapy was 23 months (95% CI 10–36 months; P < 0.03). Having the Type
A LyP variant (RR = 2.04; 95% CI 0.96–4.30) and receiving a first-line treatment
other than phototherapy (RR = 5.33; 95% CI 0.84–33.89) were significantly associ-
ated with cutaneous early relapse. Of the 252 patients, 31 (13%) had associated
mycosis fungoides unrelated to therapeutic approach, type of LyP or T-cell receptor
clonality.
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Conclusions. Current epidemiological, clinical and pathological data support previ-
ous results. Topical steroids, phototherapy and methotrexate are the most frequently
prescribed first-line treatments. Although CR and cutaneous relapse rates do not dif-
fer between them, phototherapy achieves a longer DFS. Presence of Type A LyP and
use of topical steroid or methotrexate were associated with an increased risk of early
relapse.
Introduction
Lymphomatoid papulosis (LyP)1 is considered the least
aggressive member of the group of primary cutaneous
CD30 lymphoproliferative disorders.2–4 LyP usually runs
a chronic course from years to decades, with recurrent
crops of papules or nodules that may crust and ulcerate,
then resolve. However, the clinical course seems to vary
from patient to patient, with most patients developing
flares over decades, and a significant percentage of
patients developing associated lymphomas.5 Overall,
large published series focusing on LyP are scarce, and pre-
cise treatment and follow-up data are difficult to
assess.3,6–10 Topical steroids, psoralen ultraviolet A
(PUVA) phototherapy and low-dose methotrexate are the
best-documented treatments,5 but series are short and
often do not provide data on dosage or follow-up. Treat-
ments may be followed by long-term complications,5 and
do not seem to alter the natural course of LyP, with active
disease expected at follow-up in up to 62%3 of patients.
Methods
The study was approved by the local ethics committee.
Informed consent was obtained from each participant.
Patients
Using the convenience sampling method, the Spanish
Cutaneous Lymphoma Task Force retrospectively ana-
lysed the clinical records of patients with LyP treated in
17 university hospitals in Spain between May 1986
and March 2014. All patients fulfilled the diagnostic cri-
teria of the World Health Organization (WHO) and
European Organisation for Research and Treatment of
Cancer classifications for LyP.2 The following data were
recorded for each patient: sex, age at diagnosis, interval
to diagnosis, lesion location, clinical appearance and
extent,3 histopathological type of LyP, T-cell receptor
(TCR) clonality, first-line therapy outcome, and follow-
up data. Patients were treated as per physician’s choice.
Response was graded as complete response (CR) (com-
plete disappearance of all the lesions), partial response
(PR) (> 50% reduction in skin involvement), or no
response (NR) (< 50% reduction in skin involvement,
no change in disease or worsening of disease). Cuta-
neous relapse was defined as the development of any
new lesion after CR.5 For patients achieving CR, the fol-
lowing end points were computed: time to CR, disease-
free survival (DFS) and cutaneous relapse rate. Early
relapse and late relapse were defined as the develop-
ment of new lesions within 6 months and after
12 months, respectively, following declaration of CR.
Statistical analysis
Statistical calculations were performed using SPSS
software (v19.0; IBM SPSS, Armonk, NY, USA). Sum-
mary results for continuous variables are expressed as
medians, means and interquartile ranges (IQR). Quali-
tative variables are expressed as percentages. Inter-
group differences were analysed using the Mann–
Whitney U-test or Kruskal–Wallis test for continuous
variables, and the v² or Fisher exact test for dichoto-
mous variables. Kaplan–Meier estimates of time to CR
and DFS were compared using the log-rank test. The
95% CIs were calculated. Sample size was not
planned. All P values shown are two-tailed, with
alpha of 5%, hence significance was set at P < 0.05.
Results
Patient demographics
In total, 252 patients (140 men and 112 women)
were included. Median age at diagnosis was 48 years
(range 1–80 years). There was no significant differ-
ence in LyP course in the different age groups. Median
interval to diagnosis was 6 months (range 1–
280 months), and median follow-up was 52 months
(range 1–277 months).
Disease
There was no predominant anatomical site of involve-
ment; 83% of the patients showed generalized cuta-
neous disease and none had nodal or visceral
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involvement.5 The Type A LyP variant, characterized
by a wedge-shaped dense dermal perivascular lym-
phoid infiltrate composed of small lymphocytes and
large atypical CD30+ cells with Reed–Sternberg
appearance, was seen in 70% of patients.2 Monoclonal
rearrangement of TCR was detected in 47% of
patients. A papular eruption was present in 90% of
the 252 patients at diagnosis, whereas only 30% had
ulcerated papules. Table 1 lists the main clinical fea-
tures of the included patients.
Table 1 Main clinical and pathological
findings and follow-up data. Total (N = 252) Male n = 140 Female n = 112 P
Age at diagnosis, years
Median 48 51 46 0.18*
IQR (25th–75th percentile) 35–61 37–62 34–61
Range 1–80 1–79 2–80
Time to diagnosis, months
Median 6 7 4 0.53*
IQR (25th–75th percentile) 1–25 2–28 1–21
Range 1–280 1–250 1–280
Follow-up, months
Median 52 48 52 0.79*
IQR (25th–75th percentile) 17–101 11–105 23–99
Range 1–277 1–263 1–277
Extent of skin lesions % (n)
Generalized 83 (210) 83 (116) 84 (94)
Regional 17 (42) 17 (24) 16 (18) 0.48†
T-cell receptor rearrangement % (n)
Monoclonal 47 (44) 40 (24) 59 (20) > 0.05†
Polyclonal 47 (44) 55 (33) 32 (11)
Oligoclonal 6 (6) 5 (3) 9 (3)
Pathological variant % (n)
A 70 (133) 69 (73) 72 (60) > 0.05†
B 24 (45) 22 (24) 25 (21)
C 1 (3) 1 (1) 2 (2)
D 2 (4) 4 (4) –
E 3 (5) 4 (4) 1 (1)
Type of lesion % (n)
Papules 90 (227) 89 (124) 92 (103) > 0.05†
Nodules 20 (50) 27 (38) 11 (12) 0.001†
Plaques 12 (29) 11 (16) 12 (13)
Tumours 7 (17) 9 (12) 5 (5)
Eczematous 5 (12) 7 (10) 2 (2)
Location of lesions % (n)
Limbs 92 (225) 90 (124) 94 (101)
Trunk 58 (142) 58 (80) 58 (62)
Head/neck 25 (60) 27 (37) 22 (23) > 0.05†
Mucosa 3 (8) 3 (4) 4 (4)
Disease-related survival, years, %
5 100 100 100 0.98‡
10 100 100 100
Lymphoma-related survival, years, %
5 98 96 100 0.16‡
10 98 96 100
Overall survival, years, %
5 96 96 96 0.98‡
10 96 96 96
Association with lymphoma % (n)
Mycosis fungoides 13 (31) 16 (22) 9 (10) 0.08†
Overall 14 (36) 18 (25) 9 (10)
IQR, interquartile range. *Mann-Whitney U-test; †v² or Fisher test; ‡Wilcoxon test.
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Treatment
In total, 87 patients (35%) were initially treated with
topical steroids, while 51 (20%) received systemic
methotrexate (≤ 20 mg weekly), 36 (14%) underwent
phototherapy [PUVA for 30 patients and ultraviolet
(UV)B for 6 patients] and 19 (6%) received other
treatments (topical and systemic antibiotics, dapsone,
antihistamines or oral steroids). The remaining 59
patients (23%) did not receive any treatment. First-
line therapies did not differ between men and women
(P > 0.05), or between patients with regional and
those with generalized lesions (P > 0.05).
Response
Clinical response to first-line treatment is shown in
Table 2. Of the 193 patients treated, 86 (48%)
achieved CR. No significant difference was detected
for any treatment with regard to patient sex or cuta-
neous disease extent, but having lesions with an
eczematous morphology conferred a significantly
increased relative risk (RR) of not achieving CR
(P < 0.03) (RR = 1.76; 95% CI 1.16–2.11) (supple-
mentary Table S1). Overall estimated median time to
CR was 10 months (95% CI 6–13 months), and there
was no significant difference between the analysed
treatments (P = 0.09). Of the 86 patients who
achieved CR, 67 (78%) developed cutaneous relapse,
and this rate was similar for all investigated treat-
ments (P = 0.24) (Table 2).
Overall estimated DFS (median) since CR was
11 months (95% CI 9–13 months), but DFS for
patients treated with phototherapy was significantly
longer (P < 0.03) (23 months; 95% CI 10–
36 months) (Fig. 1). Overall estimated median DFS
since first-line treatment withdrawal was 5 months
(95% CI 1–10 months) but again, this was signifi-
cantly (P < 0.02) better (23 months; 95% CI
1–50 months) for phototherapy-treated patients
(Fig. 2).
Relapse
The Type A morphological variant was significantly
(P = 0.04) more prevalent in patients who had early
relapse compared with those who had late relapse
(RR = 2.04; 95% CI 0.96–4.30). Use of a first-line
treatment other than phototherapy was recorded more
frequently in patients with early relapse than in those
with late relapse (P < 0.02) (RR = 5.33; 95% CI
0.84–33.89) (supplementary Table S2).
Mortality and comorbidities
Four patients died of unrelated diseases and three
patients died due to associated lymphomas: mycosis
fungoides (MF), Sezary syndrome and CD30 anaplastic
lymphoma kinase-negative anaplastic large cell lym-
phoma (ALCL). Table 1 lists survival data. An associ-
ated lymphoma was seen in 36 patients (14%), of
whom 31 (13%) had MF (21 men and 10 women; v²
test; P = 0.15). MF developed after LyP (median gap
42 months; range 2–92 months) in 15 patients, of
whom 5 received initial methotrexate treatment for
LyP, 5 were treated with topical steroids and 5 under-
went phototherapy. MF development showed no signif-
icant association with any type of LyP or with TCR
status (P > 0.05).
Discussion
LyP mainly develops between 45 and 52 years of
age,3,10 although several cases have been diagnosed in
young patients.11 Classic reports of LyP describe recur-
rent crops of reddish-brown papules and/or nodules
that frequently crust or ulcerate and then resolve,
often leaving atrophic scars,1,2 but in our study, we
observed this pattern in only one-third of cases. We
found that 90% of patients developed a papular erup-
tion at diagnosis, and 20% had nodules; the latter per-
centage is higher than the 3–4%3,7 previously






CR, % (n) 48 (86) 44 (34) 52 (25) 61 (20) 37 (7) > 0.05†
PR 37 (65) 33 (26) 44 (21) 30 (10) 42 (8)
NR 15 (26) 23 (18) 4 (2) 9 (3) 21 (4)
Cutaneous
relapse*
78 (67) 71 (24) 92 (23) 75 (15) 71 (5) 0.24†
CR, complete response; PR, partial response; NR, no response. *Only for patients who
achieved CR; †v² test or Fisher exact test.
Table 2 Response to first-line active treat-
ment.
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nodular lesions will help to reduce bias.5 Current data
suggest that eczematous features of LyP lesions are
significantly associated with a poorer response to treat-
ment. Widespread cutaneous involvement pre-
vails,1,2,7,9 and there is no predominant anatomical
site of involvement.3 Mucosal locations have been
described in up to 3% of patients.12
The updated WHO classification of haematological
malignancies recognizes the three original variants
(Types A, B and C) of LyP, as well as the more
recently described type D (mimics primary cutaneous
aggressive epidermotropic CD8 cytotoxic T-cell lym-
phoma), type E (angioinvasive), LyP with chromosome
6p25 rearrangement, and some even rarer variants.13
Type A is the most common LyP variant,2,4,5,10,14 and
we observed it in 70% of cases in our study. We also
found that Type A LyP was slightly but significantly
associated with early relapse. The second most fre-
quent variant was Type B LyP, which has a predomi-
nance of atypical cells with cerebriform nuclei.2,5
Clonally rearranged TCR genes have been detected
in approximately 60–70% of LyP lesions.15 We identi-
fied it in around 50% of our patients, but, in contrast
to previous reports,6,14 we did not find any correlation
between clonality and disease behaviour (supplemen-
tary Tables S1 and S2).
Grouping the most relevant studies focusing on
PUVA phototherapy,5,10,16–19 we found useful informa-
tion on response for 44 patients; CR, PR and NR rates
were 13%, 62% and 25%, respectively. Phototherapy
with UVA 120 or UVB11 was also associated with a
favourable outcome. Our study includes response data
for 33 patients treated with phototherapy as first-line
therapy, which showed higher CR rates in those
patients, highlighting the need for controlled studies.
Some authors have suggested that patients treated with
phototherapy achieve a faster response,5 but our results
do not support this hypothesis. In previous studies,
rapid relapse after therapy withdrawal was reported in
84% of the patients treated with PUVA.5,10,16–19 The
relapse rate in our study was similarly high (75%), but
DFS was longer than previously described, and was also
longer than DFS in patients who received treatments
other than phototherapy.
Single-agent chemotherapy with low-dose
methotrexate (15–25 mg weekly) seems to be effective
in controlling LyP. Results for around 150 patients
have been reported previously. In three previous large
series,10,21,22 CR and PR was achieved by 36% and
41%, respectively, of 119 patients. In our study, the
rates were 52% and 44%, respectively, of 47 treated
patients. Although satisfactory long-term control has
been described in 87% of patients with maintenance
doses,21 a relapse rate of 67–75% after drug with-
drawal has been reported.5,9,21,22 We observed an
even higher relapse rate (92%) after a short DFS (me-
dian 5 months).
Topical steroids are often used in LyP,5,10 and in
our study, they were the first-line therapy for 35% of
Figure 1 Disease-free survival since complete remission following
initial therapy.
Figure 2 Disease-free survival since the end of initial therapy
(only for patients with complete response).
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patients. A recent study on 151 patients10 reported
CR and PR in 8% and 38%, respectively, whereas we
found higher rates (44% and 33%, repecively), similar
to those achieved by the other treatments assessed.
Several additional approaches have been used in
patients with LyP,5,10 but only very limited numbers
of patients have been reported, and follow-up data are
often not available, thus they will be not discussed fur-
ther here. To our knowledge, brentuximab vedotin23 is
the only treatment that has been prospectively evalu-
ated in LyP, and induced CR in 5/9 patients.
In our study, 78% of the patients who achieved CR
after first-line active treatment relapsed, and even
higher rates have been published3,6,7,9,24 with longer
follow-up. Our study provides new data regarding time
to CR and DFS; median time to CR was 10 months
without significant differences between treatments,
while median DFS after CR was 11 months, but a sig-
nificantly longer DFS was found for patients who
received phototherapy compared with those managed
with topical steroids, methotrexate or no treatment
(Fig. 1), even after treatment withdrawal (Fig. 2).
Accordingly, first-line treatments other than photo-
therapy carry a significantly increased risk of early
relapse.
Association with lymphoma has been reported in up
to 62% of patients with LyP, but wide variability exists
between series.3–7,9,10 Our results agree with those of
a previous large series,3 in which 19% of patients had
an associated lymphoma. Referral bias and the con-
venience sampling method may partially explain the
variability between studies.7,10,25 Development of the
second lymphoma may be delayed as long as
36 years,6 making life-long follow-up of patients with
LyP essential.5 Mycosis fungoides is the most common
associated malignancy,5,6,9,10,25 followed by ALCL and
Hodgkin disease.3,10 There is not enough evidence
supporting a decreased risk of lymphoma in treated
patients,9,10 and in our study, all subsequent lym-
phomas developed in treated patients.
Conclusion
In summary, the present study supports previous clini-
cal, pathological and epidemiological findings, based
upon a large number of patients. It also enhances
knowledge about the routine initial therapeutic
approach to patients with LyP, chiefly concerning
response rates, time to response, DFS and risk factors
for relapse. However, LyP is difficult to assess by retro-
spective studies, and the commonly used convenience
sampling method carries generalizability limitations.
The consensus proposal by Kempf et al.5 is crucial for
reproducibility of future studies. They recommend that
there should be better definitions for clinical morphol-
ogy, recording of potentially useful variables and
development of a global response score. Prospective
and controlled studies are mandatory to address the
natural course of LyP, response to treatments and
prognostic biomarkers.
Learning points
• The current study reports the largest series of
patients with LyP published to date.
• The clinical, pathological and epidemiological
data support previous results.
• Topical steroids, phototherapy and methotrex-
ate are the most commonly prescribed first-line
treatments.
• CR and cutaneous relapse rates do not differ
between these treatments, but phototherapy
achieves a longer DFS time.
• Early relapse is associated with having the Type
A variant and receiving first-line treatment other
than phototherapy.
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Supporting Information
Additional Supporting Information may be found in
the online version of this article:
Table S1. Predictive variables for complete response
with first line therapy.
Table S2. Predictive variables for early (< 6 months)
vs. late (> 12 months) cutaneous relapse in patients
who achieved CR with initial therapy.
Clinical and Experimental Dermatology 7ª 2017 British Association of Dermatologists
First-line treatment in lymphomatoid papulosis  R. Fernandez-de-Misa et al.
